Organigram Holdings Inc. (TSE:OGI - Free Report) - Alliance Global Partners raised their Q3 2025 earnings per share (EPS) estimates for Organigram in a research report issued to clients and investors on Tuesday, February 11th. Alliance Global Partners analyst A. Grey now expects that the company will post earnings per share of ($0.03) for the quarter, up from their previous estimate of ($0.04). The consensus estimate for Organigram's current full-year earnings is $0.16 per share. Alliance Global Partners also issued estimates for Organigram's Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.26) EPS and FY2026 earnings at ($0.08) EPS.
Several other equities analysts have also weighed in on OGI. ATB Capital cut their target price on Organigram from C$5.25 to C$3.50 in a report on Tuesday, December 17th. Canaccord Genuity Group cut their target price on Organigram from C$3.60 to C$3.15 and set a "speculative buy" rating on the stock in a report on Monday, December 9th.
Check Out Our Latest Stock Report on Organigram
Organigram Stock Up 6.6 %
Shares of TSE:OGI traded up C$0.12 during midday trading on Friday, hitting C$1.93. 475,962 shares of the stock were exchanged, compared to its average volume of 303,282. The company has a debt-to-equity ratio of 3.07, a quick ratio of 2.62 and a current ratio of 3.36. Organigram has a 52-week low of C$1.80 and a 52-week high of C$3.95. The business's fifty day simple moving average is C$2.22 and its two-hundred day simple moving average is C$2.31. The company has a market capitalization of C$238.44 million, a PE ratio of -4.08, a P/E/G ratio of 0.42 and a beta of 1.13.
Organigram Company Profile
(
Get Free Report)
Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.
Read More
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
